Prioritizing Development A Cost Benefit Analysis of the United Nations' Sustainable Development Goals
Book contents
- Prioritizing Development
- Prioritizing Development
- Copyright page
- Contents
- Figures
- Tables
- Boxes
- Contributors
- Foreword
- Introduction
- Chapter 1 Benefits and Costs of Air Pollution Targets for the Post-2015 Development Agenda
- Chapter 2 Targets for Biodiversity and Deforestation
- Chapter 3 Benefits and Costs of the Climate Change Targets for the Post-2015 Development Agenda
- Chapter 4 Beyond Civil War
- Chapter 5 Data Revolution
- Chapter 6 Benefits and Costs of the Education Targets for the Post-2015 Development Agenda
- Chapter 7 Benefits and Costs of the Energy Targets for the Post-2015 Development Agenda
- Chapter 8 Benefits and Costs of the IFF Targets for the Post-2015 Development Agenda
- Chapter 9 Benefits and Costs of the Trade Targets for the Post-2015 Development Agenda
- Chapter 10 Benefits and Costs of the Health Targets for the Post-2015 Development Agenda
- Chapter 11 Benefits and Costs of the Noncommunicable Disease Targets for the Post-2015 Development Agenda
- Chapter 12 Benefits and Costs of the Women’s Health Targets for the Post-2015 Development Agenda
- Chapter 13 Benefits and Costs of TB Control for the Post-2015 Development Agenda
- Chapter 14 Benefits and Costs of the Infant Mortality Targets for the Post-2015 Development Agenda
- Chapter 15 Benefits and Costs of the HIV/AIDS Targets for the Post-2015 Development Agenda
- Chapter 16 Benefits and Costs of the Malaria Targets for the Post-2015 Consensus Project
- Chapter 17 Benefits and Costs of Digital Technology
- Chapter 18 Returns to Investment in Reducing Postharvest Food Losses and Increasing Agricultural Productivity Growth
- Chapter 19 Benefits and Costs of the Gender Equality Targets for the Post-2015 Development Agenda
- Chapter 20 Benefits and Costs of the Food and Nutrition Targets for the Post-2015 Development Agenda
- Chapter 21 Benefits and Costs of the Population and Demography Targets for the Post-2015 Development Agenda
- Chapter 22 Benefits and Costs of Two Science and Technology Targets for the Post-2015 Development Agenda
- Chapter 23 Global Benefits and Costs of Achieving Universal Coverage of Basic Water and Sanitation Services as part of the 2030 Agenda for Sustainable Development
- Chapter 24 Benefits and Costs of the Poverty Targets for the Post-2015 Development Agenda
- Chapter 25 Good Governance and the Sustainable Development Goals
- Conclusion
- Index
- References
Chapter 13 - Benefits and Costs of TB Control for the Post-2015 Development Agenda
Published online by Cambridge University Press: 30 May 2018
By
Edited by
Book contents
- Prioritizing Development
- Prioritizing Development
- Copyright page
- Contents
- Figures
- Tables
- Boxes
- Contributors
- Foreword
- Introduction
- Chapter 1 Benefits and Costs of Air Pollution Targets for the Post-2015 Development Agenda
- Chapter 2 Targets for Biodiversity and Deforestation
- Chapter 3 Benefits and Costs of the Climate Change Targets for the Post-2015 Development Agenda
- Chapter 4 Beyond Civil War
- Chapter 5 Data Revolution
- Chapter 6 Benefits and Costs of the Education Targets for the Post-2015 Development Agenda
- Chapter 7 Benefits and Costs of the Energy Targets for the Post-2015 Development Agenda
- Chapter 8 Benefits and Costs of the IFF Targets for the Post-2015 Development Agenda
- Chapter 9 Benefits and Costs of the Trade Targets for the Post-2015 Development Agenda
- Chapter 10 Benefits and Costs of the Health Targets for the Post-2015 Development Agenda
- Chapter 11 Benefits and Costs of the Noncommunicable Disease Targets for the Post-2015 Development Agenda
- Chapter 12 Benefits and Costs of the Women’s Health Targets for the Post-2015 Development Agenda
- Chapter 13 Benefits and Costs of TB Control for the Post-2015 Development Agenda
- Chapter 14 Benefits and Costs of the Infant Mortality Targets for the Post-2015 Development Agenda
- Chapter 15 Benefits and Costs of the HIV/AIDS Targets for the Post-2015 Development Agenda
- Chapter 16 Benefits and Costs of the Malaria Targets for the Post-2015 Consensus Project
- Chapter 17 Benefits and Costs of Digital Technology
- Chapter 18 Returns to Investment in Reducing Postharvest Food Losses and Increasing Agricultural Productivity Growth
- Chapter 19 Benefits and Costs of the Gender Equality Targets for the Post-2015 Development Agenda
- Chapter 20 Benefits and Costs of the Food and Nutrition Targets for the Post-2015 Development Agenda
- Chapter 21 Benefits and Costs of the Population and Demography Targets for the Post-2015 Development Agenda
- Chapter 22 Benefits and Costs of Two Science and Technology Targets for the Post-2015 Development Agenda
- Chapter 23 Global Benefits and Costs of Achieving Universal Coverage of Basic Water and Sanitation Services as part of the 2030 Agenda for Sustainable Development
- Chapter 24 Benefits and Costs of the Poverty Targets for the Post-2015 Development Agenda
- Chapter 25 Good Governance and the Sustainable Development Goals
- Conclusion
- Index
- References
Summary
The economic case for investment in tuberculosis (TB) control is compelling. TB control has been part of an essential package of health services for most low and middle income countries (LMICs) for decades, based on TB control’s relatively high returns. The economic case, put simply, is that TB treatment is low cost and highly effective, and on average may give an individual in the middle of their productive life around 20 additional years of life, resulting in substantial economic and health return. Yet, to date, globally TB control is underfunded, both in relative and absolute terms [1]. The most recent global estimates suggest a resource gap of around US$ 2 billion per year [2], with TB receiving less than 4% of total development assistance for health (compared to HIV receiving 25%, and maternal and child health around 20%) in 2011 [3].
- Type
- Chapter
- Information
- Prioritizing DevelopmentA Cost Benefit Analysis of the United Nations' Sustainable Development Goals, pp. 255 - 265Publisher: Cambridge University PressPrint publication year: 2018
References
Albert, H. 2004. Economic analysis of the diagnosis of smear-negative pulmonary tuberculosis in South Africa: incorporation of a new rapid test, FASTPlaqueTB, into the diagnostic algorithm. International Journal of Tuberculosis and Lung Disease 8:240–247.Google ScholarPubMed
Anderson, C, Inhaber, N, Menzies, D. 1995. Comparison of sputum induction with fiber-optic bronchoscopy in the diagnosis of tuberculosis. American Journal of Respiratory and Critical Care Medicine 152:1570–1574.Google Scholar
Andrews, JR, Lawn, SD, Rusu, C, et al. 2012. The cost-effectiveness of routine tuberculosis screening with Xpert MTB/RIF prior to initiation of antiretroviral therapy: a model-based analysis. AIDS 26:987–995. 910.1097/QAD.1090b1013e3283522d3283547.Google Scholar
Atun, R, Lazarus, JV, Van Damme, W, Coker, R. 2010a. Interactions between critical health system functions and HIV/AIDS, tuberculosis and malaria programmes. Health Policy Planning 25 Suppl 1:i1–3.Google Scholar
Atun, R, Weil, DE, Eang, MT, Mwakyusa, D. 2010b. Health-system strengthening and tuberculosis control. Lancet 375:2169–78.CrossRefGoogle ScholarPubMed
Azman, AS, Dowdy, DW. 2014. Bold thinking for bold results: modeling the elimination of tuberculosis. International Journal of Tuberculosis and Lung Disease 18:883.Google Scholar
Azman, AS, Golub, JE, Dowdy, DW. 2014. How much is tuberculosis screening worth? Estimating the value of active case finding for tuberculosis in South Africa, China, and India. BMC Medicine 12:216.CrossRefGoogle ScholarPubMed
Baltussen, R, Floyd, K, Dye, C. 2005. Cost effectiveness analysis of strategies for tuberculosis control in developing countries. BMJ 331:1364.Google Scholar
Barter, DM, Agboola, SO, Murray, MB, Barnighausen, T. 2012. Tuberculosis and poverty: the contribution of patient costs in sub-Saharan Africa – a systematic review. BMC Public Health 12:980.CrossRefGoogle ScholarPubMed
Bassett, IV, Wang, B, Chetty, S, et al. 2010. Intensive tuberculosis screening for HIV-infected patients starting antiretroviral therapy in Durban, South Africa. Clinical Infectious Diseases 51:823–9.Google Scholar
Boccia, D, Hargreaves, J, Lonnroth, K, et al. 2011. Cash transfer and microfinance interventions for tuberculosis control: review of the impact evidence and policy implications. International Journal of Tuberculosis and Lung Disease 15 Suppl 2:S37–49.Google Scholar
Burgos, JL, Kahn, JG, Strathdee, SA, et al. 2009. Targeted screening and treatment for latent tuberculosis infection using QuantiFERON-TB Gold is cost-effective in Mexico. The International Journal of Tuberculosis and Lung Disease: The Official Journal of the International Union against Tuberculosis and Lung Disease 13:962–8.Google Scholar
Chihota, VN, Grant, AD, Fielding, K, et al. 2010. Liquid vs. solid culture for tuberculosis: performance and cost in a resource-constrained setting. International Journal of Tuberculosis and Lung Disease 14:1024–31.Google Scholar
Currie, CS, Floyd, K, Williams, BG, Dye, C. 2005. Cost, affordability and cost-effectiveness of strategies to control tuberculosis in countries with high HIV prevalence. BMC Public Health 5:130.Google Scholar
Datiko, DG, Lindtjorn, B. 2010. Cost and cost-effectiveness of smear-positive tuberculosis treatment by Health Extension Workers in Southern Ethiopia: a community randomized trial. PLoS ONE 5:e9158.Google Scholar
Davis, JL, Cattamanchi, A, Cuevas, LE, Hopewell, PC, Steingart, KR. 2013. Diagnostic accuracy of same-day microscopy versus standard microscopy for pulmonary tuberculosis: a systematic review and meta-analysis. Lancet Infectious Diseases 13:147–54.CrossRefGoogle ScholarPubMed
Dawson, R, Diacon, A. 2013. PA-824, moxifloxacin and pyrazinamide combination therapy for tuberculosis. Expert Opinion on Investigational Drugs 22:927–32.Google Scholar
Denkinger, CM, Kampmann, B, Ahmed, S, Dowdy, DW. 2014a. Modeling the impact of novel diagnostic tests on pediatric and extrapulmonary tuberculosis. BMC Infectious Diseases 14:477.CrossRefGoogle ScholarPubMed
Denkinger, CM, Pai, M, Dowdy, DW. 2014b. Do we need to detect isoniazid resistance in addition to rifampicin resistance in diagnostic tests for tuberculosis? PLoS ONE 9:e84197.CrossRefGoogle ScholarPubMed
Denkinger, CM, Schumacher, SG, Boehme, CC, et al. 2014c. Xpert MTB/RIF assay for the diagnosis of extrapulmonary tuberculosis: a systematic review and meta-analysis. European Respiratory Journal 44:435–46.Google Scholar
Diacon, AH, Dawson, R, Von Groote-Bidlingmaier, F, et al. 2013. Randomized dose-ranging study of the 14-day early bactericidal activity of bedaquiline (TMC207) in patients with sputum microscopy smear-positive pulmonary tuberculosis. Antimicrobial Agents and Chemotherapy 57:2199–203.Google Scholar
Diacon, AH, Pym, A, Grobusch, MP, et al. 2014. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. New England Journal of Medicine 371:723–32.Google Scholar
Dooley, KE, Nuermberger, EL, Diacon, AH. 2013. Pipeline of drugs for related diseases: tuberculosis. Current Opinion in HIV and AIDS 8:579–85.Google Scholar
Dowdy, DW, Lourenco, MC, Cavalcante, SC, et al. 2008. Impact and cost-effectiveness of culture for diagnosis of tuberculosis in HIV-infected Brazilian adults. PLoS ONE 3:e4057.Google Scholar
Dowdy, DW, Maters, A, Parrish, N, Beyrer, C, Dorman, SE. 2003. Cost-effectiveness analysis of the gen-probe amplified mycobacterium tuberculosis direct test as used routinely on smear-positive respiratory specimens. Journal of Clinical Microbiology 41:948–53.Google Scholar
Dowdy, DW, O’Brien, MA, Bishai, D. 2008. Cost-effectiveness of novel diagnostic tools for the diagnosis of tuberculosis. International Journal of Tuberculosis and Lung Disease 12:1021–29.Google Scholar
Dowdy, DW, van’t Hoog, A, Shah, M, Cobelens, F. 2014. Cost-effectiveness of rapid susceptibility testing against second-line drugs for tuberculosis. International Journal of Tuberculosis and Lung Disease 18:647–654.Google Scholar
Dye, C, Williams, B. 2000. Criteria for the control of drug-resistant tuberculosis. Proceedings of the National Academy of Sciences 97 (14):8180–85.CrossRefGoogle ScholarPubMed
Ferroussier, O, Kumar, MKA, Dewan, PK et al. 2007. Cost and cost-effectiveness of a public-private mix project in Kannur District Kerala, India, 2001–2002. International Journal of Tuberculosis and Lung Disease 11:755–61.Google Scholar
Fitzpatrick, C, Floyd, K. 2012. A systematic review of the cost and cost effectiveness of treatment for multidrug-resistant tuberculosis. Pharmacoeconomics 30:63–80.Google Scholar
Floyd, K, Arora, VK, Murthy, KJ, et al. 2006. Cost and cost-effectiveness of PPM-DOTS for tuberculosis control: evidence from India. Bulletin of the World Health Organization 84:437–45.Google Scholar
Floyd, K, Fitzpatrick, C, Pantoja, A, Raviglione, M. 2013. Domestic and donor financing for tuberculosis care and control in low-income and middle-income countries: an analysis of trends, 2002–11, and requirements to meet 2015 targets. Lancet Global Health 1:e105–15.Google Scholar
Floyd, K, Skeva, J, Nyirenda, T, Gausi, F, Salaniponi, F. 2003. Cost and cost-effectiveness of increased community and primary care facility involvement in tuberculosis care in Lilongwe District, Malawi. International Journal of Tuberculosis and Lung Disease 7:S29–37.Google Scholar
Floyd, K, Wilkinson, D, Gilks, C. 1997. Comparison of cost effectiveness of directly observed treatment (DOT) and conventionally delivered treatment for tuberculosis: experience from rural South Africa. BMJ 315:1407–11.CrossRefGoogle ScholarPubMed
Fofana, MO, Knight, GM, Gomez, GB, White, RG, Dowdy, DW. 2014. Population-level impact of shorter-course regimens for tuberculosis: a model-based analysis. PLoS ONE 9:e96389.Google Scholar
Foster, S, Godfrey-Faussett, P, Porter, J. 1997. Modelling the economic benefits of tuberculosis preventive therapy for people with HIV: the example of Zambia. AIDS 11:919–25.Google Scholar
Gler, MT, Skripconoka, V, Sanchez-Garavito, E, et al. 2012. Delamanid for multidrug-resistant pulmonary tuberculosis. New England Journal of Medicine 366:2151–60.Google Scholar
Goodchild, M, Sahu, S, Wares, F, et al. 2011. A cost-benefit analysis of scaling up tuberculosis control in India. International Journal of Tuberculosis and Lung Disease 15:358–62.Google Scholar
Hausler, HP, Sinanovic, E, Kumaranayake, L, et al. 2006. Costs of measures to control tuberculosis/HIV in public primary care facilities in Cape Town, South Africa. Bulletin of the World Health Organization 84:528–36.Google Scholar
Hughes, R, Wonderling, D, Li, B, Higgins, B. 2012. The cost effectiveness of nucleic acid amplification techniques for the diagnosis of tuberculosis. Respiratory Medicine 106:300–7.Google Scholar
Islam, MA, Wakai, S, Ishikawa, N, Chowdhury, AM, Vaughan, JP. 2002. Cost-effectiveness of community health workers in tuberculosis control in Bangladesh. Bulletin of the World Health Organization 80:445–50.Google Scholar
Johnston, JC, Shahidi, NC, Sadatsafavi, M, Fitzgerald, JM. 2009 Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS ONE, 4:e6914.Google Scholar
Kerkhoff, AD, Kranzer, K, Samandari, T, et al. 2012. Systematic review of TST responses in people living with HIV in under-resourced settings: implications for isoniazid preventive therapy. PLoS ONE 7:e49928.Google Scholar
Khan, MS, Coker, RJ. 2014a. How to hinder tuberculosis control: five easy steps. Lancet 384:646–48.Google Scholar
Khan, MS, Coker, RJ. 2014b. Tuberculosis control: hard questions – Authors’ reply. Lancet 384:1744–45.Google Scholar
Knight, GM, Griffiths, UK, Sumner, T, et al. 2014. Impact and cost-effectiveness of new tuberculosis vaccines in low- and middle-income countries. Proceedings of the National Academy of Sciences 111:15520–25.Google Scholar
Kranzer, K, Afnan-Holmes, H, Tomlin, K, et al. 2013. The benefits to communities and individuals of screening for active tuberculosis disease: a systematic review. International Journal of Tuberculosis and Lung Disease 17:432–46.Google Scholar
Kranzer, K, Houben, RM, Glynn, JR, et al. 2010. Yield of HIV-associated tuberculosis during intensified case finding in resource-limited settings: a systematic review and meta-analysis. Lancet Infectious Diseases 10:93–102.Google Scholar
Kranzer, K, Lawn, SD, Meyer-Rath, G, et al. 2012. Feasibility, yield, and cost of active tuberculosis case finding linked to a mobile HIV service in Cape Town, South Africa: a cross-sectional study. PLoS Medicine 9:e1001281.Google Scholar
Lozano, R, Naghavi, M, Foreman, K, et al. 2012. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380:2095–128.CrossRefGoogle ScholarPubMed
Lu, C, Liu, Q, Sarma, A, et al. 2013. A systematic review of reported cost for smear and culture tests during multidrug-resistant tuberculosis treatment. PLoS ONE 8:e56074.Google Scholar
Maheswaran, H, Barton, P. 2012. Intensive case finding and isoniazid preventative therapy in HIV infected individuals in Africa: economic model and value of information analysis. PLoS ONE 7:e30457.Google Scholar
Mandalakas, AM, Hesseling, AC, Gie, RP, et al. 2013. Modelling the cost-effectiveness of strategies to prevent tuberculosis in child contacts in a high-burden setting. Thorax 68:247–55.Google Scholar
Marra, F, Marra, CA, Sadatsafavi, M et al. 2008. Cost-effectiveness of a new interferon-based blood assay, QuantiFERON-TB Gold, in screening tuberculosis contacts. International Journal of Tuberculosis and Lung Disease 12:1414–24.Google ScholarPubMed
Martinson, NA, Barnes, GL, Moulton, LH, et al. 2011. New regimens to prevent tuberculosis in adults with HIV infection. New England Journal of Medicine 365:11–20.Google Scholar
Masobe, P, Lee, T, Price, M. 1995. Isoniazid prophylactic therapy for tuberculosis in HIV-seropositive patients – a least-cost analysis. South African Medical Journal 85:75–81.Google Scholar
Menzies, NA, Cohen, T, Lin, HH, Murray, M, Salomon, JA. 2012. Population health impact and cost-effectiveness of tuberculosis diagnosis with Xpert MTB/RIF: a dynamic simulation and economic evaluation. PLoS Medicine 9:e1001347.Google Scholar
Moalosi, G, Floyd, K, Phatshwane, J, et al. 2003. Cost-effectiveness of home-based care versus hospital care for chronically ill tuberculosis patients, Francistown, Botswana. International Journal of Tuberculosis and Lung Disease 7:S80–85.Google Scholar
Mueller, DH, Mwenge, L, Muyoyeta, M, et al. 2008. Costs and cost-effectiveness of tuberculosis cultures using solid and liquid media in a developing country. International Journal of Tuberculosis and Lung Disease 12:1196–202.Google Scholar
Murray, CJ, DeJonghe, E, Chum, HJ, et al. 1991. Cost effectiveness of chemotherapy for pulmonary tuberculosis in three sub-Saharan African countries. Lancet 338:1305–08.Google Scholar
Murray, CJ, Ortblad, KF, Guinovart, C, et al. 2014. Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 384:1005–1070.Google Scholar
Murray, CJ, Vos, T, Lozano, R, et al. 2012. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380:2197–223.Google Scholar
Nganda, B, Wang’ombe, J, Floyd, K, Kangangi, J. 2003. Cost and cost-effectiveness of increased community and primary care facility involvement in tuberculosis care in Machakos District, Kenya. International Journal of Tuberculosis and Lung Disease 7:S14–20.Google Scholar
Nunn, AJ, Rusen, ID, Van Deun, A, et al. 2014. Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial. Trials 15:353.Google Scholar
Nunn, P, Williams, B, Floyd, K, et al. 2005. Tuberculosis control in the era of HIV. Nature Reviews Immunology 5:819–826.Google Scholar
Okello, D, Floyd, K, Adatu, F, Odeke, R, Gargioni, G. 2003. Cost and cost-effectiveness of community-based care for tuberculosis patients in rural Uganda. International Journal of Tuberculosis and Lung Disease 7:S72–79.Google Scholar
Orenstein, EW, Basu, S, Shah, NS, et al. 2009. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infectious Diseases 9:153–61.CrossRefGoogle ScholarPubMed
Owens, JP, Fofana, MO, Dowdy, DW. 2013. Cost-effectiveness of novel first-line treatment regimens for tuberculosis. International Journal of Tuberculosis and Lung Disease 17:590–96.Google Scholar
Oxlade, O, Falzon, D, Menzies, D. 2012. The impact and cost-effectiveness of strategies to detect drug-resistant tuberculosis. European Respiratory Journal 39:626–34.Google Scholar
Pantoja, A, Fitzpatrick, C, Vassall, A, Weyer, K, Floyd, K. 2013. Xpert MTB/RIF for diagnosis of tuberculosis and drug-resistant tuberculosis: a cost and affordability analysis. European Respiratory Journal 42:708–20.Google Scholar
Pantoja, A, Floyd, K, Unnikrishnan, KP, et al. 2009. Economic evaluation of public-private mix for tuberculosis care and control, India. Part I. Socio-economic profile and costs among tuberculosis patients. International Journal of Tuberculosis and Lung Disease 13:698–704.Google Scholar
Pantoja, A, Lonnroth, K, Lal, SS, et al. 2009. Economic evaluation of public-private mix for tuberculosis care and control, India. Part II. Cost and cost-effectiveness. International Journal of Tuberculosis and Lung Disease 13:705–12.Google Scholar
Pho, MT, Swaminathan, S, Kumarasamy, N, et al. 2012. The cost-effectiveness of tuberculosis preventive therapy for HIV-infected individuals in southern India: a trial-based analysis. PLoS ONE 7:e36001.Google Scholar
Pooran, A, Booth, H, Miller, RF, et al. 2010. Different screening strategies (single or dual) for the diagnosis of suspected latent tuberculosis: a cost effectiveness analysis. BMC Pulmonary Medicine 10:7.Google Scholar
Pooran, A, Pieterson, E, Davids, M, Theron, G, Dheda, K. 2013. What is the cost of diagnosis and management of drug resistant tuberculosis in South Africa? PLoS ONE 8:e54587.Google Scholar
Rao, NA, Anwer, T, Saleem, M. 2009. Magnitude of initial default in pulmonary tuberculosis. Journal of the Pakistan Medical Association 59:223–25.Google Scholar
Roos, BR, van Cleeff, MR, Githui, WA, et al. 1998. Cost-effectiveness of the polymerase chain reaction versus smear examination for the diagnosis of tuberculosis in Kenya: a theoretical model. International Journal of Tuberculosis and Lung Disease 2:235–41.Google Scholar
Rose, DN. 1998. Short-course prophylaxis against tuberculosis in HIV-infected persons. A decision and cost-effectiveness analysis. Annals of Internal Medicine 129:779–86.Google Scholar
Salomon, JA Lloyd-Smith, J, Getz, WM, et al. 2006. Prospects for advancing tuberculosis control efforts through novel therapies. PLoS Medicine 3 (8).Google Scholar
Samandari, T, Agizew, TB, Nyirenda, S, et al. 2011. 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial. Lancet 377:1588–98.Google Scholar
Scherer, LC, Sperhacke, RD, Ruffino-Netto, A, et al. 2009. Cost-effectiveness analysis of PCR for the rapid diagnosis of pulmonary tuberculosis. BMC Infectious Diseases 9:216.Google Scholar
Shah, M, Dowdy, D, Joloba, M, et al. 2013. Cost-effectiveness of novel algorithms for rapid diagnosis of tuberculosis in HIV-infected individuals in Uganda. AIDS 27:2883–92.Google Scholar
Shrestha, RK, Mugisha, B, Bunnell, R, et al. 2006. Cost-effectiveness of including tuberculin skin testing in an IPT program for HIV-infected persons in Uganda. International Journal of Tuberculosis and Lung Disease 10:656–62.Google Scholar
Shrestha, RK, Mugisha, B, Bunnell, R, et al. 2007. Cost-utility of tuberculosis prevention among HIV-infected adults in Kampala, Uganda. International Journal of Tuberculosis and Lung Disease 11:747–54.Google Scholar
Sinanovic, E, Kumaranayake, L. 2006a. Financing and cost-effectiveness analysis of public-private partnerships: provision of tuberculosis treatment in South Africa. Cost Effectiveness and Resource Allocation 4:11.Google Scholar
Sinanovic, E, Kumaranayake, L. 2006b. Quality of tuberculosis care provided in different models of public-private partnerships in South Africa. International Journal of Tuberculosis and Lung Disease 10:795–801.Google Scholar
Sinanovic, E, Kumaranayake, L. 2006c. Sharing the burden of TB/HIV? Costs and financing of public-private partnerships for tuberculosis treatment in South Africa. Tropical Medicine and International Health 11:1466–74.Google Scholar
Sinanovic, E, Kumaranayake, L. 2010. The motivations for participation in public-private partnerships for the provision of tuberculosis treatment in South Africa. Global Public Health 5:479–92.Google Scholar
Sinanovic, E, Ramma, L, Vassall, A, et al. 2015. Impact of reduced hospitalisation on the cost of treatment for drug-resistant tuberculosis in South Africa. International Journal of Tuberculosis and Lung Disease 19 (2):172–78.Google Scholar
Skripconoka, V, Danilovits, M, Pehme, L, et al. 2013. Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. European Respiratory Journal 41:1393–400.Google Scholar
Steingart, KR, Henry, M, Ng, V, et al. 2006. Fluorescence versus conventional sputum smear microscopy for tuberculosis: a systematic review. Lancet Infectious Diseases 6:570–81.Google Scholar
Sterling, TR, Villarino, ME, Borisov, AS, et al. 2011. Three months of rifapentine and isoniazid for latent tuberculosis infection. New England Journal of Medicine 365:2155–66.Google Scholar
Stop TB Partnership. 2006. Global plan to stop TB 2006–2015. Geneva: Stop TB Partnership.Google Scholar
Stop TB. 2008. Contributing to health systems strengthening: guidance to National Tuberculosis Programmes. Geneva: World Health Organization.Google Scholar
Sutton, BS, Arias, MS, Chheng, P, Eang, MT, Kimerling, ME. 2009. The cost of intensified case finding and isoniazid preventive therapy for HIV-infected patients in Battambang, Cambodia. International Journal of Tuberculosis and Lung Disease 13:713–18.Google Scholar
Tanimura, T, Jaramillo, E, Weil, D. Raviglione, M, Lonroth, K. 2014. Financial burden for tuberculosis patients in low- and middle-income countries: a systematic review. European Respiratory Journal 1763–75.Google Scholar
Terris-Prestholt, F, Kumaranayake, L, Ginwalla, R, et al. 2008. Integrating tuberculosis and HIV services for people living with HIV: Costs of the Zambian ProTEST Initiative. Cost Effectiveness and Resource Allocation 6:2.Google Scholar
Theron, G, Peter, J, Dowdy, D, et al. 2014a. Do high rates of empirical treatment undermine the potential effect of new diagnostic tests for tuberculosis in high-burden settings? Lancet Infectious Diseases 14:527–32.Google Scholar
Theron, G, Zijenah, L, Chanda, D, et al. 2014b. Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial. Lancet 383:424–35.Google Scholar
Uhler, LM, Kumarasamy, N, Mayer, KH, et al. 2010. Cost-effectiveness of HIV testing referral strategies among tuberculosis patients in India. PLoS ONE 5.Google Scholar
van Cleeff, M, Kivihya-Ndugga, L, Githui, W, et al. 2005. Cost-effectiveness of polymerase chain reaction versus Ziehl-Neelsen smear microscopy for diagnosis of tuberculosis in Kenya. International Journal of Tuberculosis and Lung Disease 9:877–83.Google Scholar
Vassall, A. 2013. Cost-effectiveness of introducing bedaquiline in MDR-TB regiments – an exploratory analysis. London: London School of Hygiene and Tropical Medicine.Google Scholar
Vassall, A, Bagdadi, S, Bashour, H, Zaher, H, Maaren, PV. 2002. Cost-effectiveness of different treatment strategies for tuberculosis in Egypt and Syria. International Journal of Tuberculosis and Lung Disease 6:1083–90.Google Scholar
Vassall, A, Chechulin, Y, Raykhert, I, et al. 2009. Reforming tuberculosis control in Ukraine: results of pilot projects and implications for the national scale-up of DOTS. Health Policy Planning 24:55–62.Google Scholar
Vassall, A, van Kampen, S, Sohn, H, et al. 2011. Rapid diagnosis of tuberculosis with the Xpert MTB/RIF assay in high burden countries: a cost-effectiveness analysis. PLoS Medicine 8:e1001120.Google Scholar
Wells, CD, Nelson, LJ, Laserson, KF, et al. 2007. HIV infection and multidrug-resistant tuberculosis: the perfect storm. Journal of Infectious Diseases 196 Suppl 1:S86–107.Google Scholar
World Health Organization. 2011. Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings. World Health Organization.Google Scholar
World Health Organization. 2014. Global tuberculosis report 2014. Geneva: World Health Organization.Google Scholar
World Health Organization. 2016. Factsheet: Post 2015 Global Tuberculosis Strategy. http://who.int/tb/post2015_TBstrategy.pdf?ua=1.Google Scholar
Zignol, M, van Gemert, W, Falzon, D, et al. 2012. Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007–2010. Bulletin of the World Health Organization 90:111–19D.Google Scholar
Zumla, A, Raviglione, M, Hafner, R, von Reyn, CF. 2013. Tuberculosis. New England Journal of Medicine 368:745–55.Google Scholar
Zwerling, A, White, RG, Vassall, A, et al. 2014. Modeling of novel diagnostic strategies for active tuberculosis – a systematic review: current practices and recommendations. PLoS ONE 9:e110558.Google Scholar
- 1
- Cited by